Home >> Research Area >>Others>>Others>> YL-109

YL-109

CAS# 36341-25-0

YL-109

Catalog No. BCC5543----Order now to get a substantial discount!

Product Name & Size Price Stock
YL-109: 5mg $265 In Stock
YL-109: 10mg Please Inquire In Stock
YL-109: 20mg Please Inquire Please Inquire
YL-109: 50mg Please Inquire Please Inquire
YL-109: 100mg Please Inquire Please Inquire
YL-109: 200mg Please Inquire Please Inquire
YL-109: 500mg Please Inquire Please Inquire
YL-109: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of YL-109

Number of papers citing our products

Chemical structure

YL-109

3D structure

Chemical Properties of YL-109

Cas No. 36341-25-0 SDF Download SDF
PubChem ID 5769211 Appearance Powder
Formula C14H11NO2S M.Wt 257.31
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 100 mg/mL (388.64 mM; Need ultrasonic)
Chemical Name (4E)-4-(3H-1,3-benzothiazol-2-ylidene)-2-methoxycyclohexa-2,5-dien-1-one
SMILES COC1=CC(=C2NC3=CC=CC=C3S2)C=CC1=O
Standard InChIKey GYDCERBFGYCQCZ-NTEUORMPSA-N
Standard InChI InChI=1S/C14H11NO2S/c1-17-12-8-9(6-7-11(12)16)14-15-10-4-2-3-5-13(10)18-14/h2-8,15H,1H3/b14-9+
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

YL-109 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

YL-109 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of YL-109

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.8864 mL 19.4318 mL 38.8636 mL 77.7273 mL 97.1591 mL
5 mM 0.7773 mL 3.8864 mL 7.7727 mL 15.5455 mL 19.4318 mL
10 mM 0.3886 mL 1.9432 mL 3.8864 mL 7.7727 mL 9.7159 mL
50 mM 0.0777 mL 0.3886 mL 0.7773 mL 1.5545 mL 1.9432 mL
100 mM 0.0389 mL 0.1943 mL 0.3886 mL 0.7773 mL 0.9716 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on YL-109

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. IC50 value: 85.7 nM(MCF-7 cells proliferation) [1] Target: AhR signaling activcator in vitro: YL-109 strongly inhibited cell proliferation of MCF-7 cells in a dose-dependent manner (IC50= 85.8 nM). Surprisingly, YL-109 had an anti-proliferative effect in a dose-dependent manner (IC50 = 4.02 μM) on MDA-MB-231 cells. YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhRknockdown in MDA-MB-231 cells [1]. in vivo: Mice treated with vehicle showed significantly enlarged tumors, whereas mice treated with YL-109 showed attenuated tumor growth using MCF-7 cells. Interestingly, YL-109 also suppressed tumor growth in mice injected with MDA-MB-231 cells. Compared with the vehicle control, YL-109 significantly reduced lung metastasis [1].

References:
[1]. Hiyoshi H, et al. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci Rep. 2014 Nov 18;4:7095.

Featured Products
New Products
 

References on YL-109

2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.[Pubmed:25403352]

Sci Rep. 2014 Nov 18;4:7095.

Breast cancer is the most common malignancy among women and has poor survival and high recurrence rates for aggressive metastatic disease. Notably, triple-negative breast cancer (TNBC) is a highly aggressive cancer and there is no preferred agent for TNBC therapy. In this study, we show that a novel agent, 2-(4-hydroxy-3-methoxyphenyl)-benzothiazole (YL-109), has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. In addition, YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhR knockdown in MDA-MB-231 cells. Taken together, our findings indicate that a novel agent YL-109 inhibits cell growth and metastatic potential by inducing CHIP expression through AhR signaling and reduces cancer stem cell properties in MDA-MB-231 cells. It suggests that YL-109 is a potential candidate for breast cancer therapy.

Description

YL-109 is a novel anticancer agent which has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

Keywords:

YL-109,36341-25-0,Natural Products,Others, buy YL-109 , YL-109 supplier , purchase YL-109 , YL-109 cost , YL-109 manufacturer , order YL-109 , high purity YL-109

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: